FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2481464774> ?p ?o ?g. }

• W2481464774 endingPage "3326" @default.
• W2481464774 startingPage "3316" @default.
• W2481464774 abstract "BACKGROUND High-dose, post-transplantation cyclophosphamide (PTCy) to prevent graft-versus-host disease (GVHD) has improved outcomes in haploidentical (HAPLO) stem cell transplantation (SCT). However, it remains unclear whether this strategy is effective in SCT from 1-antigen human leukocyte antigen (HLA)-mismatched unrelated donors (9/10 MUD) and how the outcomes of these patients compare with those of haploidentical transplantation recipients. METHODS A parallel, 2-arm, nonrandomized phase 2 clinical trial was conducted of melphalan-based reduced-intensity conditioning with PTCy, tacrolimus, and mycophenolate mofetil to prevent GVHD in patients with high-risk hematologic malignancies who underwent HAPLO (n = 60) or 9/10 MUD (n = 46) SCT. RESULTS The 1-year overall and progression-free survival rates were 70% and 60%, respectively, in the HAPLO arm and 60% and 47%, respectively, in the 9/10 MUD arm. The day +100 cumulative incidence of grade II to IV acute GVHD and grade III to IV acute GVHD was 28% and 3%, respectively, in the HAPLO arm and 33% and 13%, respectively, in the 9/10 MUD arm. The 2-year cumulative incidence of chronic GVHD was 24% in the HAPLO arm and 19% in the 9/10 MUD arm. The 1-year cumulative incidence of nonrelapse mortality was 21% in the HAPLO arm and 31% in the 9/10 MUD arm, and the 1-year relapse rate was 19% in the HAPLO arm and 25% in the 9/10 MUD arm. CONCLUSIONS Although this was a nonrandomized study and could not serve as a direct comparison between the 2 groups, the authors conclude that PTCy-based GVHD prophylaxis is effective for both HAPLO and 9/10 MUD SCTs. Prospective randomized trials will be required to compare the efficacies of alternative donor options for patients lacking HLA-matched donors. Cancer 2016;122:3316–3326. © 2016 American Cancer Society." @default.
• W2481464774 created "2016-08-23" @default.
• W2481464774 creator A5002039083 @default.
• W2481464774 creator A5003367392 @default.
• W2481464774 creator A5007244861 @default.
• W2481464774 creator A5010156739 @default.
• W2481464774 creator A5015342719 @default.
• W2481464774 creator A5016928938 @default.
• W2481464774 creator A5026742949 @default.
• W2481464774 creator A5029237145 @default.
• W2481464774 creator A5029855695 @default.
• W2481464774 creator A5033737136 @default.
• W2481464774 creator A5034104852 @default.
• W2481464774 creator A5035321251 @default.
• W2481464774 creator A5039574726 @default.
• W2481464774 creator A5040216854 @default.
• W2481464774 creator A5048913229 @default.
• W2481464774 creator A5050962913 @default.
• W2481464774 creator A5053904944 @default.
• W2481464774 creator A5055885795 @default.
• W2481464774 creator A5068834306 @default.
• W2481464774 creator A5069460930 @default.
• W2481464774 creator A5072832956 @default.
• W2481464774 creator A5073053011 @default.
• W2481464774 creator A5074147173 @default.
• W2481464774 creator A5075342012 @default.
• W2481464774 creator A5085076031 @default.
• W2481464774 creator A5086144565 @default.
• W2481464774 creator A5086302165 @default.
• W2481464774 creator A5086825472 @default.
• W2481464774 creator A5088175930 @default.
• W2481464774 creator A5089295627 @default.
• W2481464774 creator A5091083304 @default.
• W2481464774 date "2016-07-12" @default.
• W2481464774 modified "2023-10-16" @default.
• W2481464774 title "Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation" @default.
• W2481464774 cites W1978164777 @default.
• W2481464774 cites W1982767302 @default.
• W2481464774 cites W1985075230 @default.
• W2481464774 cites W2017000328 @default.
• W2481464774 cites W2017908149 @default.
• W2481464774 cites W2020172209 @default.
• W2481464774 cites W2034544947 @default.
• W2481464774 cites W2035592289 @default.
• W2481464774 cites W2036785154 @default.
• W2481464774 cites W2039334806 @default.
• W2481464774 cites W2044467556 @default.
• W2481464774 cites W2055553511 @default.
• W2481464774 cites W2065434970 @default.
• W2481464774 cites W2069363178 @default.
• W2481464774 cites W2070231921 @default.
• W2481464774 cites W2079023050 @default.
• W2481464774 cites W2111951140 @default.
• W2481464774 cites W2125606779 @default.
• W2481464774 cites W2126021331 @default.
• W2481464774 cites W2159575415 @default.
• W2481464774 cites W2160666689 @default.
• W2481464774 cites W2166247867 @default.
• W2481464774 cites W2167357955 @default.
• W2481464774 cites W2169530433 @default.
• W2481464774 cites W2234309584 @default.
• W2481464774 cites W2317642686 @default.
• W2481464774 cites W2558143048 @default.
• W2481464774 cites W3122459650 @default.
• W2481464774 cites W4251178308 @default.
• W2481464774 cites W4377470768 @default.
• W2481464774 doi "https://doi.org/10.1002/cncr.30180" @default.
• W2481464774 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5459484" @default.
• W2481464774 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27404668" @default.
• W2481464774 hasPublicationYear "2016" @default.
• W2481464774 type Work @default.
• W2481464774 sameAs 2481464774 @default.
• W2481464774 citedByCount "70" @default.
• W2481464774 countsByYear W24814647742017 @default.
• W2481464774 countsByYear W24814647742018 @default.
• W2481464774 countsByYear W24814647742019 @default.
• W2481464774 countsByYear W24814647742020 @default.
• W2481464774 countsByYear W24814647742021 @default.
• W2481464774 countsByYear W24814647742022 @default.
• W2481464774 countsByYear W24814647742023 @default.
• W2481464774 crossrefType "journal-article" @default.
• W2481464774 hasAuthorship W2481464774A5002039083 @default.
• W2481464774 hasAuthorship W2481464774A5003367392 @default.
• W2481464774 hasAuthorship W2481464774A5007244861 @default.
• W2481464774 hasAuthorship W2481464774A5010156739 @default.
• W2481464774 hasAuthorship W2481464774A5015342719 @default.
• W2481464774 hasAuthorship W2481464774A5016928938 @default.
• W2481464774 hasAuthorship W2481464774A5026742949 @default.
• W2481464774 hasAuthorship W2481464774A5029237145 @default.
• W2481464774 hasAuthorship W2481464774A5029855695 @default.
• W2481464774 hasAuthorship W2481464774A5033737136 @default.
• W2481464774 hasAuthorship W2481464774A5034104852 @default.
• W2481464774 hasAuthorship W2481464774A5035321251 @default.
• W2481464774 hasAuthorship W2481464774A5039574726 @default.
• W2481464774 hasAuthorship W2481464774A5040216854 @default.
• W2481464774 hasAuthorship W2481464774A5048913229 @default.
• W2481464774 hasAuthorship W2481464774A5050962913 @default.
• W2481464774 hasAuthorship W2481464774A5053904944 @default.

• next